ABSTRACT The in vivo and in vitro immune response after in vivo immunization with pneumococcal polysaccharides (PPS) has been analyzed in man. Substantial differences were noted in this system when compared with human responses to soluble protein antigens. Within 6 d after immunization, specific PPS antigen-binding cells (ABC), specific plaque-forming cells (PFC), and cells capable of spontaneously synthesizing in vitro large amounts of specific anti-PPS immunoglobulin (Ig) G, IgA, and lesser amounts of specific IgM appeared in the peripheral blood. The ABC, PFC, and the total amount of specific spontaneous antibody production followed nearly identical kinetics after immunization. Low doses of irradiation markedly inhibited spontaneous anti-PPS antibody production by lymphocytes obtained 7 cific B cells by PWM vs. specific antigen, and the in vivo and in vitro unresponsiveness to in vivo booster immunization with PPS, contrast sharply with previous studies in man with soluble protein antigens such as keyhole limpet hemocyanin and tetanus toxoid. Furthermore, the lack of T cell activation by PPS also contrasts with previous results with tetanus toxoid and other protein antigens. This system should prove useful in delineating certain aspects of human B cell physiology not readily approachable with standard soluble protein antigens.
INTRODUCTION
Since the humoral immune response to capsular polysaccharides is an important host defense mechanism against many pathogenic bacteria, the serologic response to infection and immunization with polysaccharides in man is an area of considerable interest. Yet little is known concerning the immune response to these antigens at the cellular level in man. In contrast, polysaccharides have been valuable tools in probing the heterogeneity and regulation of murine B cell reactivity. Much of the advantage of the use of polysaccharide antigens in the study of B cell physiology in the mouse resides in their significant differences from protein antigens and the feasibility of their use in approaching certain aspects of B cell activation and immunoregulation that do not readily lend themselves to study with the standard soluble protein and particulate antigens. For (3) and IgM and IgG2 in man (4) . Finally, responses to polysaccharides arise later in ontogeny than do responses to protein antigens, and adult levels are not reached until 8 wk in mice (5) and 2 yr in man (6) .
To more precisely delineate the immune response to polysaccharides at the cellular level in man, methodologies recently developed for the study of soluble antigen-induced and antigen-specific triggering of human B cells with protein antigens (7, 8) were adapted to the in vitro study of human lymphoid cells after in vitro immunization with the pneumococcal polysaccharide (PPS)' vaccine. As a result, a system was established for examining in vitro B cells spontaneously secreting Ig specific for PPS, and substantial differences from the in vitro immune response to soluble protein antigens were demonstrated.
METHODS
Immunizations. Normal male volunteers, aged [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (9) . The resulting T cell-enriched suspensions were 92-96% rosette-positive. T cell depletion was accomplished by treating the SRBC-negative population with the anti-T cell hybridoma antibody Leu-1 (Becton, Dickinson & Co., Oxnard, CA) and rabbit serum (Dutchland Laboratories Inc., Denver, PA) as a source of complement as previously described (7) . Depletion of T cells was monitored by assessing the blastogenic response of the T celldepleted (TCD) population to T cell mitogens. Monocyte depletion was performed by plate adherence (10) .
Culture conditions. Cultures for measuring blastogenesis were performed as previously described (11) Cultures were incubated in a 5% CO2 atmosphere at 370C and rocked at 4 cycles/min. Some cultures were washed free of antigen on day 4. Cell densities were 1.5 X 106 unfractionated (UF) mononuclear cells/ml or 0.5 X 106 TCD cells/ ml. Cultures for the determination of the spontaneous secretion of Ig were harvested at day 5, while cultures measuring antigen-and PWM-induced supernatant Ig were harvested at day 10. Supernatants were decanted and stored at 40C until assay, usually within 3 d.
Preparation of polysaccharide-coated SRBC and ox RBC. PPS vaccine was rendered free of preservative and phosphate by dialysis against normal saline. For each milliliter of packed RBC, 1 mg of type III PPS or 1.4 mg of PPS vaccine in 1 ml of normal saline was added, followed by 10 ml of a 0.01% solution of chromic chloride (J. T. Baker Chemical Co., Phillipsburg, NJ) in normal saline. This suspension was incubated in a water bath at 30'C for 40 min, washed, and stored at 40C in Hanks' balanced salt solution.
Plaque-forming cell (PFC) assay. Cells secreting antibody specific for PPS were detected by using a hemolytic PFC assay originally described by Gronowicz et al. (12) and modified by Fauci et al. (13) for detecting total Ig-secreting cells with staphylococcal protein A-coated SRBC. PPS-coated SRBC were substituted for the staphylococcal protein Acoated SRBC. Developing antiserum was an IgG fraction of rabbit anti-human Ig serum (Cappel Laboratories, Inc., Cochranville, PA). No developing antisera was used when direct PFC were counted.
Antigen-binding cell (ABC) assay. 0.2 ml of UF mononuclear cells at 1 x 107 cells/ml was mixed with 0.2 ml of ox RBC (1 X 108/ml) coated with PPS. Cells were spun for 10 min at 500 rpm at 10C and then placed on ice for 30 min. The button was gently resuspended and rosettes were counted with a hemocytometer. No ABC were detected with ox RBC coated with chromic chloride, and rosette formation could be inhibited by preincubating mononuclear cells with 100 jig of PPS.
Assays. Specific antibody production was measured by using an enzyme-linked immunosorbent assay as previously described (14) with minor modifications. Flat-bottomed 96-well microtiter plates were first coated with 0.1 ml of a carbonate buffer, pH 9.6, containing 10 jg/ml of PPS types 3, 8, or 14, or 140 Ag/ml of whole PPS vaccine and allowed to incubate overnight at 370C. Plates were then washed three times with phosphate-buffered saline containing 0.05% Tween 20. Samples were appropriately diluted, added to duplicate wells in a volume of 0.1 ml, and incubated at room temperature for 2 h. The plates were then washed as before and 0.1 ml of a 1:1,000 dilution of heavy chain-specific goat anti-human IgG, IgA, or IgM conjugated to alkaline phosphate (Sigma Chemical Co., St. Louis, MO) was added to each well. The plates were incubated overnight at 4°C, washed again, and then allowed to react with 0.1 ml/well of a l-mg/ml solution of p-nitrophenyl phosphate (Sigma Chemical Co.) in a pH 8.6 carbonate buffer containing 0.001 M MgCl2. The subsequent development of color was measured by using a multi-channel spectrophotometer (Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, VA) and related to that seen with a standard serum rich in anti-PPS (IgG, IgA, IgM). One PPSM or PPSA unit was defined as the amount of PPS-specific IgM or IgA, respectively, present in a 1:10,000 dilution of immune serum and a PPSG unit was defined as the amount of PPS-specific IgG present in 1:100,000 dilution of immune serum. One vaccine PPSM unit is approximately equal to 0.6 ng of antibody, one vaccine PPSA unit is approximately equal to 0. 
RESULTS
Kinetics of spontaneous antibody production. After immunization with PPS vaccine, lymphoid cells appeared in the peripheral blood that were spontaneously secreting specific antibody directed against the polysaccharides present in the vaccine. This spontaneous production of specific antibody was detected by measuring supernatant antibody production of peripheral blood mononuclear cells after 5 d in culture in the absence of in vitro stimulation with antigen. Fig. 1 demonstrates the kinetics of this response in a representative individual studied at various intervals after in vivo immunization. The amount of total specific IgG, IgM, and IgA anti-PPS antibody against all 14 serotypes is displayed. This spontaneous secretion of antibody by peripheral blood lymphocytes was first detectable on day 6, peaked on day 8, and disappeared by day 13 with no subsequent reappearance. Identical results were found when the response against type 8 alone was measured (data not shown). Substantial (Fig. 2) suggesting that they were actively dividing in vitro and that this cell division over a restricted period of time was critical for the expression of their spontaneous antibody-secreting capability. 500 rad of irradiation reduced the amount of spontaneous IgG PPSspecific antibody production by 75%. In addition, the protein synthesis inhibitor cycloheximide (15 Ag/ml) completely abrogated any anti-PPS antibody production (data not shown).
A series of additional studies were performed attempting to enhance or to suppress specific in vitro antibody production. Fig. 3 (18) . To assess the effect of booster immunization with PPS on spontaneous anti-PPS antibody secretion, a previously immunized donor whose lymphoid cells had synthesized large quantities of spontaneous anti-PPS antibody was boosted with 0.5 ml of the PPS-vaccine 4 mo after the initial immunization. 4 by unactivated T cells, T cell factors, or antigen; however, they were readily inhibited by low doses of irradiation and a protein synthesis inhibitor, as well as by PWM. By 2 wk after immunization, spontaneous secretion of anti-PPS antibody by peripheral blood lymphocytes could no longer be detected. However, specific antibody production could be induced with PWM subsequent to the disappearance of spontaneously secreting cells from the circulation. Despite extensive manipulations, peripheral blood mononuclear cells could not be induced by in vitro antigen to secrete specific antibody up to 1 yr postimmunization.
Since most individuals are exposed to pneumococcal antigens during childhood, the human immune response to the PPS vaccine may represent a secondary response. Nevertheless, in many respects the human in vitro and in vivo immune response to PPS parallels the response to this antigen in mice. There is a requirement for in vivo priming with antigen, a lack of secondary in vitro response with antigen stimulation, a period of prolonged unresponsiveness after immunization (19) , lack of T cell activation as measured by T cell proliferation (17) , and a possible regulatory role for nonspecific T cell suppression (20) . The (24) (25) (26) (27) (28) , particularlv with regard to the appearance of spontaneously secreting cells and the subsequent PWM-inducible specific antibody production. One of the major differences between the two systems is the lack of a detectable T cell response in the PPS system. We interpret this later finding to reflect either a true thymus independence of the response or an absence of lPPSspecific T cells within the circulating T cell repertoire.
The absence of B cell memory in murine studies has also been attributed to the T cell independence of the system (29, 30) . It has been shown that type III PPS can induce an IgG memory response only if it is coupled to a thymus-dependent carrier such as horse RBC (31) . As in the mouse, booster immunization of humans with the PPS vaccine is not accompanied by a memory response (18) .
The appearance of lymphoblastoid B cells in the peripheral blood after in vivo perturbation of the human immune system appears to be a general phenomenon and has been demonstrated after immunization with protein antigens such as tetanus toxoid (26) , after intranasal inoculation with a cold-adapted influenza virus (32), after immunization with Salmonella typhi (33) , and in the present study after immunization with PPS. During the peak of the response after immunization with PPS, 1-3% of the peripheral blood lymphocytes formed rosettes with ox RBC coated with PPS and 0.1% formed spontaneous PFC in a hemolysis-ingel PFC assay. Thus, lymphoblastoid B cells specific for PPS represent a relatively large proportion of the peripheral blood B cell pool. A possible explanation for the 10-fold difference in ABC and PFC frequencies is the likelihood that ABC assays detect cells in various states of differentiation, whereas the PFC assay identifies only B cells that are actively secreting anti-PPS antibody.
The origin, destination, and regulation of these lymphoblastoid B cells are presently not understood. Since the spleen plays a major role in the immune response to PPS (34) , these cells may originate there. The bone marrow has been reported to be a major source of Ig production and may be the final destination of these cells (35) . Of note is the fact that the lymphoblastoid B cells are sensitive to low levels of irradiation in that spontaneous secretion of antibody can be markedly inhibited by exposure to 500 rad. Thus, at least a proportion of them appear to be proliferating and this level of proliferation may be essential for the full expression of antibody-secreting capability. Results in the present study show that these lymphoblastoid cells are not modified by unactivated T cells or by T cell factors present in a mixed lymphocyte reaction supernatant, but are suppressed by PWM in culture. The role of antiidiotype, T cell suppression, and immune complexes on the proliferation and differentiation of these cells is currently under investigation.
In conclusion, a PEC assay, an ABC assay, and an in vitro culture system for examining B cells actively synthesizing and secreting anti-PPS antibody after in vivo immunization have been described for man, and a close analogy between the human and murine immune response to PPS was found. The dichotomy between PWM and antigen in triggering anti-PPS antibody after immunization with PPS contrasts with previous results in man with KLH and tetanus toxoid antigens, and may be related to the absence of PPSspecific T cell help. Thus, this system may prove useful in delineating the mechanisms of activation and immunoregulation of subsets of human B cells not amenable to study with the commonly used soluble protein antigens.
